Joanne P. LaGanke MS Center

North Central Neurology Associates, P.C.

Click here to edit subtitle

Past Clinical Trials

Vaccinex: A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single=Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous XXXX in Patients with Multiple Sclerosis. Closed to enrollment.


SYNERGY

Biogen Idec: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of XXXX in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex. Closed to enrollment.


PREFER MS 

Novartis:  A 12-Month, Prospective, Randomized, active-controlled, open-label study to evaluate patient retention of XXXX vs. approved first-line disease modifying therapies in adults with relapsing remitting multiple sclerosis. Closed to enrollment.


ASSESS

Novartis: A 12-month, randomized, rater and dose-blinded study to compare the efficacy and safety of XXXX 0.25mg and 0.5mg administered orally once daily with XXXX 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis. Closed to enrollment.


EMPIRE

Genzyme, A Sanofi Company: A Phase 2a/2b double-blind, randomized, placebo-controlled study assessing efficacy, safety, and dose-response of XXXX in patients with relapsing-remitting multiple sclerosis (RRMS). Closed to enrollment.


TRANSITION

Novartis: A multicenter, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from XXXX to Gilenya.


ENHANCE

Biogen Idec: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release XXXX 10mg, Administered Twice Daily in Subjects with Multiple Sclerosis. Closed to enrollment.


CAMMS

Genzyme, A Sanofi Company: An Extension Protocol for the Multiple Sclerosis Patients Who Participated in Genzyme Sponsored Studies of XXXX. Closed to enrollment.


TOPAZ

Genzyme, A Sanofi Company: A long-term follow-up study for Multiple Sclerosis patients who have completed the XXXX Extension Study. Closed to enrollment.


CONFIDENCE

Teva: A Multinational, Multi-center, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous Injections of XXXX 40mg/mL Three Times a Week Compared to 20mg/mL Daily. Closed to enrollment.


REDEFINE

EMD Serono: A phase IV, randomized, prospective, US-based, multi-center, cross-over study evaluating subject's ease-of-use with XXX, XXX, and XXX autoinjectors in subjects with relapse remitting multiple sclerosis (RRMS) treated with XXXX 44mcg subcutaneously three times a week. Closed to enrollment.


IVSS

Genzyme, A Sanofi Company:A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course. Closed to enrollment.